In this episode, we discuss the diagnosis and management of primary myelofibrosis with Dr. Ayalew Tefferi at Mayo Clinic, Rochester, Minnesota. Here are the show notes, including key studies discussed in this episode:

1. Risk stratification of PMF:
MIPSS70 Score: http://www.mipss70score.it
https://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886

Genetically inspired prognostic scoring system (GIPSS):
https://www.nature.com/articles/s41375-018-0107-z

Type 1 CALR mutation:
https://ashpublications.org/blood/article/124/15/2465/33454

MYSEC-PM:
http://www.mysec-pm.eu
https://www.nature.com/articles/leu2017169

2. Treatment of PMF with JAK inhibitors
https://pubmed.ncbi.nlm.nih.gov/36680511/

Momelotinib:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02036-0/fulltext

Pacritinib : https://ashpublications.org/blood/article/140/Supplement%201/1518/490663
https://jamanetwork.com/journals/jamaoncology/fullarticle/2674384

Fedratinib:
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18284

3. Allogeneic Transplant in PMF
https://ashpublications.org/hematology/article/2021/1/453/482995

Black African-American patients with primary myelofibrosis
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022009611/494460

4. Imtelestat in PMF
https://www.nejm.org/doi/full/10.1056/NEJMoa1310523